department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Tavalisse · pharmadog

pharmadog
drugs
Tavalisse

drug

patient view →

fostamatinib disodium

Marketedupdated 2mo ago

by $RIGL RIGEL PHARMACEUTICALS INC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Tavalisse

generic

fostamatinib disodium

indication

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 6, 2028

~2.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (28)

Jul 27, 2032formulationUS 8771648
Jul 27, 2032formulationUS 8771648
Jul 27, 2032method-of-use (U-2294)US 8951504
Jul 27, 2032method-of-use (U-2294)US 8951504
Sep 4, 2031compositionUS 7449458
Sep 4, 2031compositionUS 7449458
Nov 24, 2030formulationUS 82631224.4y
Nov 24, 2030formulationUS 82631224.4y
Nov 6, 2028formulationUS 86524922.3y
Nov 6, 2028formulationUS 86524922.3y
Jun 17, 2026compositionUS 8163902
Jun 17, 2026compositionUS 8163902
Jun 17, 2026formulationUS 8445485
Jun 17, 2026formulationUS 8445485
Jun 17, 2026method-of-use (U-2294)US 8912170
Jun 17, 2026method-of-use (U-2294)US 8912170
Jun 17, 2026method-of-use (U-2294)US 9283238
Jun 17, 2026method-of-use (U-2294)US 9283238
Jun 12, 2026compositionUS 7989448
Jun 12, 2026compositionUS 7989448
Mar 28, 2026compositionUS 7538108
Mar 28, 2026compositionUS 7538108
Jan 19, 2026compositionUS 8211889
Jan 19, 2026compositionUS 8211889
Jan 19, 2026method-of-use (U-2294)US 9266912
Jan 19, 2026method-of-use (U-2294)US 9266912
Jan 19, 2026formulationUS RE48898
Jan 19, 2026formulationUS RE48898

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying fostamatinib disodium

phase3Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)completedn=123
phase3A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHAcompletedn=90